Fig. 4

Effect of STK11 and/or- KEAP1 Mutations on OS in Patients With aNSCLC in the 1L* With (A) KRAS WT or (B) KRAS G12C and in the 2L^† With (C) KRAS WT or (D) KRAS G12C. 1L, first line; 2L, second line; aHR, adjusted hazard ratio; aNSCLC, advanced non-small cell lung cancer; ns, non-significant; OS, overall survival; PD-L1, programmed cell death 1 ligand 1; TMB, tumor mutational burden; WT, wildtype. * Adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, and histology. ^† Adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, histology, and drug category in the 1L. ^‡ HR comparing STK11 WT-KEAP1 WT vs mSTK11 and/or mKEAP1